Montagu Private Equity and Kohlberg & Company have acquired Teleflex Inc.’s vascular access and interventional product lines in a $1.5 billion carve-out transaction, announced January 20, 2026. This deal values the unit at approximately 14x 2025 EBITDA on $650 million in revenue, with Teleflex receiving $1.4 billion in net proceeds. The acquisition, expected to close in H2 2026, highlights private equity’s increasing focus on healthcare carve-outs, leveraging operational improvements and geographic expansion in a consolidating medtech market. This transaction signals a broader industry trend where public companies streamline portfolios through asset-level divestitures, driving significant PE activity in fragmented sectors.
- Target Business
- Teleflex Inc.’s vascular access and interventional product lines
- Acquirers
- Montagu Private Equity and Kohlberg & Company
- Transaction Type
- Carve-out acquisition
- Enterprise Value
- $1.5 billion
- 2025 Revenue (Target)
- $650 million
- 2025 EBITDA (Target)
- $107 million
- Valuation Multiple (Revenue)
- 2.3x 2025 revenue
- Valuation Multiple (EBITDA)
- 14x 2025 EBITDA
- Announced Date
- January 20, 2026
- Expected Close
- Second half of 2026
- Seller Net Proceeds
- $1.4 billion
- Advisors (Buyers)
- Kirkland & Ellis (legal)
Montagu Private Equity and Kohlberg & Company have agreed to acquire a medical device business from Teleflex Inc. in a $1.5 billion carve-out transaction, marking one of the largest healthcare carve-outs in recent private equity activity. The deal, announced January 20, 2026, targets Teleflex’s vascular access and interventional product lines, which generated approximately $650 million in revenue in 2025.
Most “AI for Diligence” tools are lying to you. The truth is, they are just ChatGPT wrappers. Experience what real AI for Diligence looks like, built like Claude Code, but for M&A/ PE Diligence:
💼 When Claude Code Marries Due Diligence!
Deal Structure and Financial Terms
The transaction values the carved-out unit at an enterprise value of $1.5 billion, implying a 2.3x multiple on 2025 revenue and roughly 14x EBITDA, based on preliminary figures from Teleflex’s filings. Montagu and Kohlberg will fund the acquisition with a mix of equity commitments and debt financing led by a syndicate including JPMorgan Chase and Antares Capital. Teleflex expects to receive $1.4 billion in net proceeds after adjustments, bolstering its balance sheet for shareholder returns and debt reduction.
Closing is targeted for the second half of 2026, subject to customary regulatory approvals, including Hart-Scott-Rodino clearance. Kirkland & Ellis advised Montagu and Kohlberg, while Latham & Watkins represented Teleflex.
Strategic Rationale and Company Backgrounds
The target comprises Teleflex’s vascular access portfolio, including catheter insertion kits and guidewires used in minimally invasive procedures. This segment faced margin pressure from supply chain disruptions and pricing headwinds in 2024-2025 but offers growth potential amid rising demand for outpatient surgeries. Teleflex, a Wayne, Pennsylvania-based medtech firm with $3.1 billion in total 2025 revenue, has pursued portfolio optimization since spinning off its anesthesia business in 2023.
Montagu, managing $14 billion in assets, and Kohlberg, with $6 billion under management, bring complementary expertise in healthcare carve-outs. Montagu’s prior investments include Convatec’s advanced wound care unit, while Kohlberg exited its stake in Haemonetics’ plasma business at a 3x return in 2024. The buyers plan to invest in R&D and commercial expansion, targeting 8-10% annual growth through geographic diversification into Asia-Pacific markets.
| Metric | Value ($M) | Margin (%) |
|---|---|---|
| Revenue | 650 | — |
| EBITDA | 107 | 16.5 |
| Enterprise Value | 1,500 | 14.0x |
Synergies, Operational Changes, and Industry Context
Post-acquisition, the unit will operate independently as Vascular Solutions Group, retaining 1,200 employees with no immediate layoffs planned. Montagu and Kohlberg aim to leverage operational improvements, drawing from Bain & Company’s 2025 healthcare report, which highlights 15-20% EBITDA uplift potential in medtech carve-outs through supply chain consolidation and SG&A reductions.
This deal aligns with surging private equity interest in healthcare carve-outs, up 35% year-over-year per PitchBook data through Q4 2025. McKinsey’s January 2026 M&A outlook notes medtech as a top sector for 2026, driven by aging demographics and elective procedure backlogs, with average multiples compressing to 12-15x from 2023 peaks amid higher interest rates.
- Regulatory Risks: Minimal antitrust concerns given the unit’s 5-7% U.S. market share in vascular access.
- Exit Horizon: 4-6 years via IPO or strategic sale, per KKR’s 2025 PE playbook on medtech investments.
- Comparable Deals: Carlyle’s $2.2 billion buyout of Baxter’s BioPharma unit (2024, 13x EBITDA); GTCR’s $900 million carve-out of BD’s enteral feeding business (2025).
Broader Implications for Healthcare M&A and Private Equity Strategies
The transaction underscores a shift toward asset-level deals in medtech, enabling public companies like Teleflex to streamline portfolios amid 2025’s 12% decline in overall M&A volume, per Goldman Sachs research. For private equity, it exemplifies “buy-and-build” strategies in fragmented vascular markets, with cross-border M&A trends 2026 pointing to Europe as a bolt-on target. Deal advisors anticipate similar carve-outs from J&J and Medtronic, potentially totaling $10 billion in healthcare divestitures this year.
Teleflex shares rose 4% in after-hours trading following the announcement, reflecting investor approval of the valuation in a cautious market.
Sources
